BioSpace News Archive

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that it will host a live conference call and audio webcast on Friday, August 13, 2021 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2021 and to provide a business overview.

The rapidly rising popularity of microneedling as a popular medical spa procedure among a considerable chunk of the individuals will prove to be a good growth generator.

The gastrointestinal system comprises the gastrointestinal tract and accessory organs. The gastrointestinal system is a long hollow tube that extends from the oral cavity where food enters the body, via the esophagus, stomach, small intestine, large intestine, rectum, and finally to the anus where undigested food is expelled out of the body.

The demand in the global clinical laboratory tests market is expected to increment at a healthy CAGR during the forecast period of 2017 to 2025, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, prevalence of target diseases, growing demand for early detection of chronic diseases, and the introduction of innovative solutions.

Polpharma Biologics Group announces that its joint venture company with Santo Holding, Bioeq, has submitted a biologics license application to the U.S. Food and Drug Administration for their biosimilar candidate of the ophthalmological drug Ranibizumab.

Oncolytics Biotech® Inc. announced that the Company will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference, which is taking place virtually from August 10-12, 2021.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced financial results for the second quarter ended June 30, 2021 and highlighted recent activity.

PLx Pharma Inc., a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg, announced certain financial and operational results for the three and six months ended June 30, 2021.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced that the Company will release its second quarter 2021 financial results before the open of the U.S. financial markets on Friday, August 13, 2021.

Nunzi Pharmaceutical Corporation (OTC:NUNZ) entered into a License Agreement with Michael Mitsunaga as stated in the 8K filing of 08/05/2021.